By Sukriti Gupta, Sanchayaita Roy and Twesha Dikshit (Reuters) -European shares ended lower on Tuesday, dragged down by heavyweight financial and healthcare stocks as investors awaited news on a ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...

New Report Covers PolyPid's Latest Developments; After Blockbuster Phase 3 Results in Surgical Infection Prevention, Could This Israeli Innovator Become Big Pharma’s Most Coveted Acquisition ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Adventurous speculators interested in a quick-strike opportunity may want to set their sights on Novo Nordisk (NYSE: NVO ).

If you have $1,000 to invest right now, you may be wondering where to get started. You could buy stocks that are flying high ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

Novo Nordisk, PayPal, and Dell Technologies are modestly priced growth stocks with a lot of potential to rise higher. Buying ...

Novo Nordisk today announced a collaboration with the American Society of Haematology (ASH) to support the Consortium on Newborn Screening in Africa (CONSA) Community Health Worker (CHW) Initiative.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...